Who can use Koselugo(Selumetinib)?

Selumetinib is an oral small-molecule kinase inhibitor and a selective inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2). 

Who can use Koselugo(Selumetinib)?

By inhibiting the activity of MEK1/2 proteins, it blocks the RAS/RAF/MEK/ERK signaling pathway, thereby suppressing tumor cell proliferation and survival.

Selumetinib is primarily indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1). It can significantly reduce tumor volume and improve related clinical symptoms.